Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity

Vaccine

Volumn 30, Issue 22, 2012, Pages 3329-3338

  Mancebo, A ^a   Casaco A ^b   Gonzalez B ^a   Ledon N ^b   Sorlozabal, J ^b   Leon A ^a   Gomez D ^a   Gonzalez Y ^a   Bada, A M ^a   Gonzalez C ^a   Arteaga, M E ^a   Ramirez H ^b   Fuentes, D ^a  

^a National Center for Laboratory Animal Breeding (CENPALAB)   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Epidermal growth factor; Immunotherapy; Relevant specie; Repeat dose toxicity; Vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CANCER VACCINE; CHOLESTEROL; CIMAVAX EGF VACCINE; CREATININE; EPIDERMAL GROWTH FACTOR; GLUCOSE; HEMOGLOBIN; MONTANIDE ISA 51; POTASSIUM; PROTEIN; SODIUM; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; URIC ACID;

ADRENAL GLAND; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPSY; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; BRAIN; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYST; DRUG TOLERABILITY; ENZYME ACTIVITY; EOSINOPHIL COUNT; ERYTHROCYTE COUNT; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GRANULOMA; HEART; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOGENICITY; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; KIDNEY; LEUKOCYTE COUNT; LIVER; LUNG; LYMPHOCYTE COUNT; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MONOCYTE; MORTALITY; NEUTROPHIL COUNT; NONHUMAN; OVARY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RECTUM TEMPERATURE; REPEATED DRUG DOSE; SODIUM BLOOD LEVEL; SPLEEN; THROMBOCYTE COUNT; THYMUS; TOXICITY TESTING; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; VACCINATION;

ANIMALS; ANTIBODIES; ASPARTATE AMINOTRANSFERASES; BLOOD CELL COUNT; BODY TEMPERATURE; BODY WEIGHT; CANCER VACCINES; DRUG TOXICITY; FEEDING BEHAVIOR; FEMALE; HISTOCYTOCHEMISTRY; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLES; RATS; RATS, SPRAGUE-DAWLEY; SERUM; VACCINATION;

EID: 84859854199     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.092     Document Type: Article

References (58)

1. Jemal A., Bray F., Center M.M., Ferlay A., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Albright C., Garst J. Vaccine therapy in non-small-cell lung cancer. Curr Oncol Rep 2007, 9:241-246.
3. Press M.F., Lenz H.J. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007, 67:2045-2075.
4. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009, 21:177-184.
5. Damia G., D'Incalci M. Contemporary pre-clinical development of anticancer agents-what are the optimal preclinical models. Eur J Cancer 2009, 45:2768-2781.
6. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
7. Abbasi S., Badheeb A. Prognostic factors in advanced non-small-cell lung cancer patients: patient characteristics and type of chemotherapy. Lung Cancer Int 2011, 2011:4. Article ID 152125. 10.4061/2011/152125.
8. Rusch V., Baselga J., Cordon-Cardo C. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53:2379-2385.
9. González G., Crombet T., Catalá M., Mirabal V., Hernández J.C., González Y., et al. A novel vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a Pilot Clinical Trial. Ann Oncol 1998, 9:431-435.
10. Shin D.M., Donato N.J., Perez-Soler R. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001, 5:1204-1207.
11. Crombet T., Torres L., Solano M. Pharmacological and clinical evaluation of the humanized anti-epidermal growth factor receptor monoclonal antibody, hR3, in patients with advanced epithelial carcinomas. Proc Am Soc Clin Oncol 2002, 21:254a. (Abstr 1012).
12. Rodríguez P.C., Rodríguez G., González G., Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small cell lung cancer therapy. MEDDIC Rev 2010, 12:17-23.
13. Gonzalez G., Lage A. Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr Cancer Drug Targets 2007, 7:229-241.
14. González G., Crombet T., Torres F., Catalá M., Alfonso L., Osorio M., et al. Epidermal growth factor-based cancer vaccine for non-small cell lung cancer therapy. Ann Oncol 2003, 14:461-466.
15. Crombet T., Neninger E., Catalá M., García B., Leonard I., Martínez L., et al. Treatment of NSCLC patients with an EGF-based cancer vaccine. Report of a Phase I Trial. Cancer Biol Ther 2006, 5:145-159.
16. González G., Crombet T., Neninger E., Viada C., Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer. Analysis of pooled data from three clinical trials. Hum Vaccines 2007, 3:8-13.
17. Neninger E., de la Torre A., Osorio M., Catalá M., Bravo I., Mendoza M., et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cal-lung cancer. J Clin Oncol 2008, 26:1452-1458.
18. García B., Neninger E., de la Torre A., Leonard I., Martínez R., Viada C., et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008, 14:840-846.
19. Neninger E., García B., Crombet T., Viada C., Pereda S., Leonard I., et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced non small cell lung cancer. J Immunol 2009, 32:92-99.
20. ICHS4 Duration of chronic toxicity testing in animals (rodent and non-rodent toxicity testing) 1998.
21. Clarke J., Hurst C., Martin P., Vahle J., Ponce R., Mounho B., et al. Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?. Regul Toxicol Pharmacol 2008, 50:2-22.
22. Mellstedt H., Vansteenkiste J., Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011, 73:11-17.
23. Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., Green J., et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 2009, 54:164-182.
24. ICH ICH S6. Preclinical safety evaluation of biotechnology-derived pharmaceuticals 1997, http://www.ich.org [accessed 21.10.09].
25. Gonzalez G., Crombet T., Lage A. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment. Curr Cancer Drug Targets 2011, 11:103-110.
26. Simpson R.J., Smith J.A., Moritz R.L., O'Hare M.J., Rudland P.S., Morrison J.R., et al. Rat epidermal growth factor: complete amino acid sequence. Eur J Biochem 1985, 153:629-637.
27. Bada A., Casacó A., Arteaga M.E., Martínez J., León A., Santana E., et al. Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study. Hum Exp Toxicol 2002, 21:263-267.
28. Bada A.M., Casacó A., Mancebo A., Fuentes D., González B., Hernández O., et al. Acute and repeated dose intramuscular toxicity of GM3 cancer vaccine in SD rats. Pak J Biol Sci 2005, 8:1045-1050.
29. Yamanaka M., Hiramatsu K., Hirahara T. Pathological studies on local tissue reactions in guinea pigs and rats caused by four different adjuvants. J Vet Med Sci 1992, 54:685-692.
30. Leenaars P.P.A.M., Koedam M.A., Wester P.W., Baumans V., Claassen E., Hendriksen C.F.M. Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice. Lab Anim 1998, 32:387-406.
31. CERB Centre de Recherches Biologiques (CERB) Report 20050623TRB. Montanide ISA 51 VG. 18-Week intramuscular toxicity study in rats, Baugy, France; 2006.
32. Aucouturier J., Dupuis L., Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19:2666-2672.
33. Miles A.P., Saul A. Extraction and characterization of vaccine antigens from water-in-oil adjuvant formulations. Methods Mol Biol 2005, 308:293-300.
34. Graham B.S., McElrath M.J., Keefer M.C., Rybczyk K., Berger D. Immunization with cocktail of HIV-derived peptides in Montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS ONE 2010, 5:11995.
35. Aucouturier J., Ascarateil S., Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006, 24. S2/44-S2/45.
36. Hardegree M.C., Pittman M. Influence of antigens on release of free fatty acids from ArlacelA (mannide monooleate). Proc Soc Exp Biol Med 1966, 123:179-184.
37. Buitner D., Wollnik F. Spontaneous short-term fluctuations in the daily pattern of heart rate, body temperature and locomotor activity in the laboratory rat. Lab Anim 1982, 16:319-326.
38. Saper C.B. Neurobiological basis of fever. Ann N Y Acad Sci 1998, vol. 856:90-94. M.J. Kluger, T. Bartfai, C.A. Dinarello (Eds.).
39. Scales W.E., Kluger M.J. Effect of antipyretic drugs on circadian rhythm in body temperature of rats. Am J Physiol Regul Integr Comp Physiol 1987, 253:306-313.
40. Michel C., Cabanac M. Opposite effects of gentle handling on body temperature and body weight in rats. Physiol Behav 1999, 67:617-622.
41. Gonlugur U., Gongulur T.E. Non-allergic eosinophilic inflammation. Immunol Invest 2006, 35:29-45.
42. Blanchard C., Rothenberg M.E. Biology of the eosinophil. Adv Immunol 2009, 101:81-121.
43. Lampinen M. Cytokine-regulated eosinophil migration in inflammatory disorders. Clinical and experimental studies. Acta Universitatis Upsaliensis. Comprehensive summaries of Uppsala Dissertations from the Faculty of Medicine, vol. 971. Uppsala; 2000. 66 pp.
44. Co D.O., Hogan L.H., Il-Kim S., Sandor M. T cell contribution to the different phases of granuloma formation. Immunol Lett 2004, 92:135-142.
45. Wang H.B., Ghiran I., Matthaei K., Weller P.F. Airway eosinophils: allergic inflammation recruited professional antigen-presenting cells. J Immunol 2007, 179:7585-7592.
46. Maletto B.A., Ropolo A.S., Alignani D.O., Liscovsky M.V., Ranocchia R.P., Moron V.G. Presence of neutrophil-bearing antigen in lymphoid organs of immune mice. Blood 2006, 108:3094-3102.
47. Chertov O., Ueda H., Xu L.L., Tani K., Murphy W.J., Wang J.M. Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med 1997, 186:739-747.
48. Bennouna S., Bliss S.K., Curiel T.J., Denkers E.Y. Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol 2003, 171:6052-6058.
49. Ozer J., Ratner M., Shaw M., Bailey W., Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008, 245:194-205.
50. Boone L., Meyer D., Cusick P., Ennulat D., Provencher A., Everds N., et al. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol 2005, 34:182-188.
51. Ramaiah S.K. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem Toxicol 2007, 45:1551-1557.
52. Amacher D.E. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 1998, 27:119-130.
53. Amacher D.E. A toxicologist's guide to biomarkers of hepatic response. Hum Exp Toxicol 2002, 21:253-262.
54. Carakostas M.C., Gossett K.A., Church G.E., Cleghorn B.L. Evaluating toxin-induced hepatic injury in rats by laboratory results and discriminant analysis. Vet Pathol 1986, 23:264-269.
55. Boyd J.W. Serum enzymes in the diagnosis of disease in man and animals. J Comp Pathol 1988, 98:381-404.
56. Blair P.C., Thompson M.B., Wilson R.E., Esber H.H., Maronpot R.R. Correlation of changes in serum analytes and hepatic histopathology in rats exposed to carbon tetrachloride. Toxicol Lett 1991, 55:149-159.
57. Travlos G.S., Morris R.W., Elwell M.R., Duke A., Rosenblum S., Thompson M.B. Frequency and relationship of clinical chemistry and liver and kidney histopathology findings in 13-week toxicity studies in rats. Toxicology 1996, 107:17-29.
58. Ward M.J., Uno H., Frith H.C. Immunohistochemistry and morphology of reactive lesions in lymph nodes and spleen from rats and mice. Toxicol Pathol 1993, 21:199-205.